Akari Therapeutics, Plc
Advancing Next-Generation Antibody Drug Conjugates Designed with Novel ImmunoOncology Payloads
17 employees · est. 2015 · London, United Kingdom
Pheon Therapeutics
Pheon is an Antibody-Drug Conjugate specialist developing next generation ADCs for a range of hard-to-treat cancers.
26 employees · est. 2022 · London, United Kingdom
Akari Therapeutics, Plc is the older company (2015 vs 2022).
2 signals in the last 90 days
Side-by-Side Comparison
| Metric | Akari Therapeutics, Plc | Pheon Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2015 older | 2022 |
| Headquarters | ||
| Headquarters | London, United Kingdom | London, United Kingdom |
| Employees | ||
| Employees | 17 | 26 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health Care | Biotechnology, Health and Wellness, Life Sciences |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Series B |
| Total Funding | ||
| Total Funding | $114.25M | $188.00M |
| Funding Rounds | ||
| Funding Rounds | 5 | 4 |
| Services | ||
| Services | Not tracked yet | Development of Antibody-Drug Conjugates, Clinical Development of Cancer Therapies, Research in Oncology |
| Target Customers | ||
| Target Customers | Not tracked yet | Healthcare Professionals, Oncologists, Cancer Treatment Centers, Pharmaceutical Distributors |
| Taxonomy | ||
| Taxonomy | Autoimmune Diseases, Inflammatory Diseases, Nomacopan, Clinical Trials, Pediatric Medicine, Hematopoietic Stem Cell Transplant, Orphan Drug Designation, Fast Track Designation, Rare Pediatric Disease Designation, European Commission, Pre-clinical Research, Complement C5 Activation, Leukotriene B4 Activity, Geographic Atrophy | Antibody-Drug Conjugates (ADCs), Oncology, Hard-to-Treat Cancers, ADC Development, Monoclonal Antibodies, Proprietary Payload Platform, Drug Discovery, Solid Tumors, Novel Mechanism Of Action, Clinical Strategy, Medicinal Chemistry, Healthcare Investment, Pharmaceutical Research |
| Website | ||
| Website | akaritx.com | pheontx.com |
About Akari Therapeutics, Plc
Akari Therapeutics, Plc is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The company's pipelin...
About Pheon Therapeutics
Pheon Therapeutics, founded in 2022, is a promising player in the biotechnology, health and wellness, and life sciences sectors, with headquarters in the United Kingdom. The company specializes in developing next-generation Antibody-Drug Conjugates (ADCs) to tackle hard-to-treat cancers, as highligh...
We will tell you when either one moves
BounceWatch watches Akari Therapeutics, Plc and Pheon Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Akari Therapeutics, Pl... and Pheon Therapeutics — by email.
Frequently Asked Questions
Compare Akari Therapeutics, Plc with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Akari Therapeutics, Plc on 9 Jun 2026, and Pheon Therapeutics on 29 Apr 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
